Product Code: DIMI0490
DelveInsight's "Sepsis - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Sepsis epidemiology and market outlook for the 7MM.
Sepsis, also referred to as blood poisoning or septicaemia, is a potentially life-threatening condition, triggered by an infection or injury. The disease is characterized by an overwhelming immune response to infection. The body releases immune chemicals into the blood to combat the infection. Those chemicals trigger widespread inflammation, which leads to blood clots and leaky blood vessels. As a result, blood flow is impaired, and that deprives organs of nutrients and oxygen and leads to organ damage. In severe cases, one or more organs fail. In the worst cases, blood pressure drops, the heart weakens, and the patient spirals toward septic shock. Once this happens, multiple organs-lungs, kidneys, liver-may quickly fail, and the patient can die. Sepsis is a major challenge in hospitals, where it's one of the leading causes of death. It is also a main reason why people are readmitted to the hospital. Sepsis occurs unpredictably and can progress rapidly. The disease id generally caused by many types of microbes, including bacteria, fungi, and viruses. However, bacteria are the most common cause of Sepsis.
Common symptoms of sepsis are fever, chills, rapid breathing and heart rate, rash, confusion, and disorientation. Many of these symptoms are also common in other conditions, making sepsis difficult to diagnose, especially in its early stages.
Markets Covered:
- United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2016-2028
Sepsis Understanding and Treatment Algorithm:
The market report provides the overview of the Sepsis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Sepsis Epidemiology:
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Sepsis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Sepsis Product Profiles & Analysis:
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Sepsis Market Outlook:
The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Sepsis market.
Sepsis Market Share by Therapies:
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Sepsis Report Insights:
- Patient Population in Sepsis
- Therapeutic Approaches in Sepsis
- Sepsis Pipeline Analysis
- Sepsis Market Size and Trends
- Sepsis Market Opportunities
- Impact of upcoming Therapies in Sepsis
Sepsis Report Key Strengths:
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Sepsis Report Assessment:
- Current Treatment Practices in Sepsis
- Unmet Needs in Sepsis
- Market Attractiveness
- Market Drivers and Barriers
Key Benefits:
- The report will help to develop Business Strategies by understanding the trends shaping and driving the Sepsis market
- Organize sales and marketing efforts by identifying the best opportunities for Sepsis market
- To understand the future market competition in the Sepsis market.
Table of Contents
1. Report Introduction
2. Sepsis Market Overview at a Glance
- 2.1. Market Share Distribution of Sepsis in 2016
- 2.2. Market Share Distribution of Sepsis in 2028
3. Disease Background and Overview: Sepsis
- 3.1. Introduction
- 3.2. Symptoms
- 3.3. Etiology
- 3.4. Risk Factors
- 3.5. Pathophysiology
- 3.6. Diagnosis
- 3.7. Treatment
4. Epidemiology and Patient Population
- 4.1. Key Findings
- 4.2. Total Prevalent/ Incident Patient Population of Sepsis in 7MM
- 4.3. Total Prevalent Patient Population of Sepsis in 7MM - By Countries
5. Epidemiology of Sepsis by Countries
- 5.1. United States
- 5.1.1. Assumptions and Rationale
- 5.1.2. Prevalent/Incident Cases of the Sepsis
- 5.1.3. Sub-Type Specific cases of the Sepsis *
- 5.1.4. Sex- Specific Cases of the Sepsis *
- 5.1.5. Diagnosed Cases of the Sepsis
- 5.1.6. Treatable Cases of the Sepsis
- 5.2. EU5
- 5.3. Assumptions and Rationale
- 5.4. Germany
- 5.4.1. Assumptions and Rationale
- 5.4.2. Prevalent/Incident Cases of the Sepsis
- 5.4.3. Sub-Type Specific cases of the Sepsis *
- 5.4.4. Sex- Specific Cases of the Sepsis *
- 5.4.5. Diagnosed Cases of the Sepsis
- 5.4.6. Treatable Cases of the Sepsis
- 5.5. France
- 5.5.1. Assumptions and Rationale
- 5.5.2. Prevalent/Incident Cases of the Sepsis
- 5.5.3. Sub-Type Specific cases of the Sepsis *
- 5.5.4. Sex- Specific Cases of the Sepsis *
- 5.5.5. Diagnosed Cases of the Sepsis
- 5.5.6. Treatable Cases of the Sepsis
- 5.6. Italy
- 5.6.1. Assumptions and Rationale
- 5.6.2. Prevalent/Incident Cases of the Sepsis
- 5.6.3. Sub-Type Specific cases of the Sepsis *
- 5.6.4. Sex- Specific Cases of the Sepsis *
- 5.6.5. Diagnosed Cases of the Sepsis
- 5.6.6. Treatable Cases of the Sepsis
- 5.7. Spain
- 5.7.1. Assumptions and Rationale
- 5.7.2. Prevalent/Incident Cases of the Sepsis
- 5.7.3. Sub-Type Specific cases of the Sepsis *
- 5.7.4. Sex- Specific Cases of the Sepsis *
- 5.7.5. Diagnosed Cases of the Sepsis
- 5.7.6. Treatable Cases of the Sepsis
- 5.8. United Kingdom
- 5.8.1. Assumptions and Rationale
- 5.8.2. Prevalent/Incident Cases of the Sepsis
- 5.8.3. Sub-Type Specific cases of the Sepsis *
- 5.8.4. Sex- Specific Cases of the Sepsis *
- 5.8.5. Diagnosed Cases of the Sepsis
- 5.8.6. Treatable Cases of the Sepsis
- 5.9. Japan
- 5.9.1. Assumptions and Rationale
- 5.9.2. Prevalent/Incident Cases of the Sepsis
- 5.9.3. Sub-Type Specific cases of the Sepsis *
- 5.9.4. Sex- Specific Cases of the Sepsis *
- 5.9.5. Diagnosed Cases of the Sepsis
- 5.9.6. Treatable Cases of the Sepsis
6. Current Treatment & Medical practices
- 6.1. Treatment Algorithm
- 6.2. Treatment Guidelines
7. Unmet Needs of the Sepsis
8. Marketed Therapies
- 8.1. Drug A: Company 1
- 8.1.1. Drug Description
- 8.1.2. Mechanism of Action
- 8.1.3. Regulatory Milestones
- 8.1.4. Advantages & Disadvantages
- 8.1.5. Product Profile
- 8.2. Drug B: Company 2
- 8.2.1. Drug Description
- 8.2.2. Mechanism of Action
- 8.2.3. Regulatory Milestones
- 8.2.4. Advantages & Disadvantages
- 8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Sepsis
- 11.1. Drug C: Company 3
- 11.1.1. Drug Description
- 11.1.2. Clinical Trials Details
- 11.1.3. Safety and Efficacy Profile
- 11.1.4. Advantages & Disadvantages
- 11.1.5. Pipeline Development Activities
- 11.1.6. Product Profile
- 11.2. Drug D: Company 4
- 11.2.1. Drug Description
- 11.2.2. Clinical Trials Details
- 11.2.3. Safety and Efficacy Profile
- 11.2.4. Advantages & Disadvantages
- 11.2.5. Pipeline Development Activities
- 11.2.6. Product Profile
12. Sepsis : 7MM Market Analysis
- 12.1. 7MM Market Size of Sepsis
- 12.2. 7MM Percentage Share of drugs marketed for Sepsis
- 12.3. 7MM Market Sales of Sepsis by Products
13. Sepsis : Country-Wise Market Analysis
- 13.1. United States
- 13.1.1. Market Size of Sepsis in United States
- 13.1.2. Percentage Share of drugs marketed for Sepsis in United States
- 13.1.3. Market Sales of Sepsis by Products in United States
- 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2. EU-5
- 13.2.1. Germany
- 13.2.1.1. Market Size of Sepsis in Germany
- 13.2.1.2. Percentage Share of drugs marketed for Sepsis in Germany
- 13.2.1.3. Market Sales of Sepsis by Products in Germany
- 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2.2. France
- 13.2.2.1. Market Size of Sepsis in France
- 13.2.2.2. Percentage Share of drugs marketed for Sepsis in France
- 13.2.2.3. Market Sales of Sepsis by Products in France
- 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2.3. Italy
- 13.2.3.1. Market Size of Sepsis in Italy
- 13.2.3.2. Percentage Share of drugs marketed for Sepsis in Italy
- 13.2.3.3. Market Sales of Sepsis by Products in Italy
- 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2.4. Spain
- 13.2.4.1. Market Size of Sepsis in Spain
- 13.2.4.2. Percentage Share of drugs marketed for Sepsis in Spain
- 13.2.4.3. Market Sales of Sepsis by Products in Spain
- 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2.5. United Kingdom
- 13.2.5.1. Market Size of Sepsis in United Kingdom
- 13.2.5.2. Percentage Share of drugs marketed for Sepsis in United Kingdom
- 13.2.5.3. Market Sales of Sepsis by Products in United Kingdom
- 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.3. Japan
- 13.3.1. Market Size of Sepsis in Japan
- 13.3.2. Percentage Share of drugs marketed for Sepsis in Japan
- 13.3.3. Market Sales of Sepsis by Products in Japan
- 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Indication Specific
